The Catapult International (ASX: CAT) H1 FY 2025 results have pushed the Catapult share price well above $3. Is the move justified?

My thesis is broken due to my changing view of management.

.

Virologist injects herself with novel cancer treatment, reducing tumour size in weeks.

Xero’s half year report showed its ability to increase prices in Australia, but hinted at a more difficult competitive situation in the USA.

Thesis creep saw me hesitate to sell, but I should have done it a year ago.

Record corporate tax collected as Coalition senators seek to water down further measures.

Hispanic voters less likely to support a candidate who uses gender-neutral term “Latinx”.

Regulatory risk is real, but management retains my confidence.

Carbon dioxide levels in classrooms high enough to cause cognitive impairment.

.

After selling a few, and having a few taken over, I thought I’d make a list of the current buy and hold recommendations.

There was nothing much to celebrate arising from the Alcidion AGM and Q1 FY 2025 update.

AI training centre demand drives major players’ embrace of nuclear.